Get the Stockscreener App
297.45
1.02%
-3.06
After Hours:
297.45
Alnylam Pharmaceuticals Inc stock is traded at $297.45, with a volume of 681.26K.
It is down -1.02% in the last 24 hours and down -4.23% over the past month.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
See More
Previous Close:
$300.51
Open:
$299.12
24h Volume:
681.26K
Relative Volume:
0.63
Market Cap:
$39.71B
Revenue:
$4.29B
Net Income/Loss:
$577.22M
P/E Ratio:
70.68
EPS:
4.2086
Net Cash Flow:
$641.34M
1W Performance:
+3.65%
1M Performance:
-4.23%
6M Performance:
-31.84%
1Y Performance:
+2.92%
1-Day Range:
$294.99
$303.33
1-Week Range:
$284.38
$303.33
52-Week Range:
$284.19
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals Inc
Sector
Industry
Phone
(617) 551-8200
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-07-26 | Resumed | Oppenheimer | Outperform |
| Aug-04-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-04-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-30-25 | Resumed | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Mar-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-12-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-16-24 | Upgrade | Goldman | Neutral → Buy |
| Feb-16-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Oct-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| May-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-26-23 | Initiated | SMBC Nikko | Neutral |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Buy |
| Sep-09-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-27-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-07-22 | Initiated | William Blair | Outperform |
| Apr-25-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-03-22 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-22-21 | Upgrade | Goldman | Neutral → Buy |
| Nov-22-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-04-21 | Upgrade | UBS | Neutral → Buy |
| Aug-04-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-22-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-30-20 | Resumed | Berenberg | Hold |
| Sep-08-20 | Initiated | Citigroup | Buy |
| Aug-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| May-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-24-20 | Resumed | Evercore ISI | Outperform |
| Mar-19-20 | Initiated | Berenberg | Buy |
| Dec-19-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-20-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-06-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-05-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-23-19 | Initiated | UBS | Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-18 | Reiterated | Stifel | Buy |
| Aug-07-18 | Upgrade | Stifel | Hold → Buy |
| May-04-18 | Reiterated | Stifel | Hold |
| Mar-28-18 | Initiated | Evercore ISI | In-line |
View All
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
Assessing Alnylam Pharmaceuticals (ALNY) Valuation After Mixed Share Performance And Strong AMVUTTRA Uptake - simplywall.st
Director at Alnylam (NASDAQ: ALNY) granted RSUs and stock options - Stock Titan
Alnylam (NASDAQ: ALNY) awards RSUs and options to board director - Stock Titan
Director at Alnylam (NASDAQ: ALNY) receives RSUs and options - Stock Titan
Alnylam (ALNY) director gets new RSUs, options and reports trust holdings - Stock Titan
Director Peter Kellogg granted RSUs and stock options at Alnylam (NASDAQ: ALNY) - Stock Titan
ALNY (ALNY) director granted 671 RSUs and 1,441 options at $298.48 - Stock Titan
Alnylam (ALNY) director Olivier Brandicourt receives new RSU and option grants - Stock Titan
ALNY (ALNY) director Dennis Ausiello granted RSUs and stock options awards - Stock Titan
Alnylam (ALNY) director granted RSUs and stock options in new equity awards - Stock Titan
Discipline and Rules-Based Execution in ALNY Response - Stock Traders Daily
Ionis, Alnylam, BioMarin up as Citi starts at buy on catalyst and growth outlook - MSN
Alnylam Pharmaceuticals’ SWOT analysis: stock faces margin pressure By Investing.com - Investing.com South Africa
Alnylam Pharmaceuticals’ SWOT analysis: stock faces margin pressure - Investing.com
Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y Growth - Eastern Progress
Alnylam Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
ALNY Technical Analysis & Stock Price Forecast - Intellectia AI
ALNY Initiated Coverage by Citigroup -- Price Target Set at $380 - GuruFocus
Citi Initiates Coverage on Biotech Stocks: Ionis (IONS), Alnylam (ALNY), BioMarin (BMRN) - GuruFocus
Ionis, Alnylam, BioMarin are new Buys at Citi (ALNY:NASDAQ) - Seeking Alpha
Alnylam Issues 2025 Corporate Responsibility Report - BioSpace
How HELIOS-B Phase 3 Vutrisiran Data and Real-World Evidence Expansion Will Impact Alnylam (ALNY) Investors - simplywall.st
Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout - Proactive financial news
Citigroup initiates coverage of Alnylam Pharmaceuticals (ALNY) with buy recommendation - MSN
Daily Brief Health Care: Dermavon Holdings, Alebund Pharmaceuticals Jiangsu, Alnylam Pharmaceuticals, Artrya , Bavarian Nordic A/S, Cardinal Health, Dexcom Inc, American Shared Hospital Servi, Eli Lilly & Co, Abeona Therapeutics and more - Smartkarma
Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment - GlobeNewswire Inc.
How Investors Are Reacting To Alnylam Pharmaceuticals (ALNY) New HELIOS-B Vutrisiran Data And Real-World Study - Yahoo Finance
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by iA Global Asset Management Inc. - MarketBeat
Alnylam’s Vutrisiran Data And Real-World Study Contrast With Depressed Valuation - Yahoo Finance
Alnylam Pharmaceuticals, Inc. $ALNY Position Reduced by DNB Asset Management AS - MarketBeat
Is the options market predicting a spike in Alnylam Pharmaceuticals stock? - MSN
ALNY Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by ANTIPODES PARTNERS Ltd - MarketBeat
Alnylam Pharmaceuticals Adjusts Valuation Grade Amid Strong Financial Performance Indicators - Markets Mojo
A Look At Alnylam Pharmaceuticals (ALNY) Valuation As HELIOS B Data And TTR Guidance Reassure Investors - simplywall.st
ALNY Stock Price, Quote & Chart | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
Alnylam teams up with Viz.ai and American Heart Association to advance ATTR-CM care - MSN
Alnylam reiterates 2026 TTR sales guidance of $4.4B-$4.7B while expanding TRITON-CM enrollment to about 1,750 - MSN
Alnylam (NASDAQ: ALNY) director exercises 11,250 stock options at $70.20 - Stock Titan
Is Alnylam (ALNY) One of the Best Aggressive Growth Stocks to Buy? - Insider Monkey
Capital World Investors holds 10.9M Alnylam shares (NASDAQ: ALNY) - Stock Titan
Capital Research holds 9.47M shares of Alnylam (NASDAQ: ALNY) in 13G/A - Stock Titan
Alnylam Pharmaceuticals stock (US02005N1000): Backs TTR revenue outlook amid AMVUTTRA growth - AD HOC NEWS
5 Best Aggressive Growth Stocks to Buy According to Wall Street Analysts - Insider Monkey
Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build - sharewise.com
ALNY: Strong AMVUTTRA growth, ambitious pipeline, and robust cash position drive future expansion - TradingView
Morgan Stanley Increases Price Goal on Alnylam Pharmaceuticals, Inc. (ALNY) - Insider Monkey
Alnylam Pharmaceuticals stock (US02005N1000): Q1 earnings beat and vutrisiran data - AD HOC NEWS
Alnylam (ALNY) Reports Positive Phase 3 Results for Vutrisiran i - GuruFocus
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden - BioSpace
Heart drug vutrisiran tied to fewer deaths in ATTR-CM patients - Stock Titan
Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.41%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):